[Form 4] Predictive Oncology Inc. Insider Trading Activity

Rhea-AI Filing Summary

Predictive Oncology insider grant and holdings summary

Director Daniel E. Handley was granted 64,680 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting, and the award is scheduled to vest in full on October 31, 2025, subject to continued service through that date. The RSUs were granted at a recorded price of $0.00. Following the grant, the reporting person beneficially owns 81,698 shares. The Form 4 indicates a single reporting person filed for this transaction.

Positive

• 64,680 RSUs granted which convert one‑for‑one to common shares upon vesting
• Beneficial ownership increased to 81,698 shares following the reported acquisition
• RSUs vest in full on October 31, 2025, providing a clear vesting date

Negative

• None.

Insights

Financial Analyst

TL;DR: A director received a sizeable RSU award that increases reported beneficial ownership but is time‑based and subject to service.

The grant of 64,680 RSUs increases the director's reported economic stake to 81,698 shares once vested, which could modestly align management incentives with shareholders. The award is time‑based, vesting in full on October 31, 2025, and carries no cash purchase price as reported. This is a routine equity compensation event and does not, by itself, provide information about operating performance or capital structure changes beyond the prospective share issuance upon vesting.

Corporate Governance Expert

TL;DR: The RSU grant appears to be a standard service‑conditioned equity award for a director, increasing disclosed ownership.

The RSUs explicitly convert one‑for‑one to common shares and vest contingent on continued service through the vesting date, which is a common retention mechanism. The Form 4 shows the transaction code for an acquisition and a zero dollar recorded price, consistent with a grant rather than a purchase. There is no disclosure in this filing of accelerated vesting, performance conditions, or changes to compensation policy.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HANDLEY DANIEL E

(Last) (First) (Middle)

C/O PREDICTIVE ONCOLOGY INC.

91 43RD STREET, SUITE 110

(Street)

PITTSBURGH PA 15201

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Predictive Oncology Inc. [ POAI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A		64,680(1)	A	$0.00	81,698	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The grant consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs shall vest in full on October 31, 2025, subject to continued service through the applicable vesting date.

	/s/ Josh Blacher, Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Predictive Oncology director Daniel E. Handley acquire on 09/09/2025 (POAI)?

He was granted 64,680 restricted stock units (RSUs), each representing the right to one share of common stock upon vesting.

When do the RSUs granted to Daniel E. Handley vest?

The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date.

How many shares does Daniel E. Handley beneficially own after the grant?

Following the reported transaction, he beneficially owns 81,698 shares.

What price was recorded for the RSU grant on the Form 4?

The transaction is reported with a recorded price of $0.00, consistent with a grant of RSUs.

Was the Form 4 filed by more than one reporting person?

No. The form indicates it was filed by one reporting person.